translation agency

GS 840 (adefovir dipivoxil): broad-spectrum antiviral trial, CD4 count under 100.
James JS; Clearinghouse, AIDS Newsletter Database, P.O. Box 6003,
June 30, 1997
AIDS Treat News. 1997 Feb 7;(No 264):4-5. Unique Identifier : AIDSLINE

A study is seeking more than 2,000 volunteers for a phase III trial of GS 840 (also called adefovir dipivoxil, or bis-POM PMEA), to test whether the drug, taken orally once a day, can increase survival of persons with advanced HIV, and also whether it can prevent the development of CMV disease. GS 840 is known to be active against cytomegalovirus (CMV), hepatitis B, HHV6 (human herpes virus 6), Epstein-Barr virus, and to have some modest activity against HIV. In this study, participants will continue their regular antiviral treatments, and add GS 840 or placebo once a day. More information can be obtained by calling the AIDS Clinical Trials Information Service or Gilead Sciences Medical Information.

*Acquired Immunodeficiency Syndrome/DRUG THERAPY *Anti-HIV Agents/THERAPEUTIC USE